Post COVID-19 and Long COVID Symptoms in Otorhinolaryngology—A Narrative Review
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(2), P. 506 - 506
Published: Jan. 14, 2025
Post/Long
COVID
(syndrome)
is
defined
as
a
condition
with
symptoms
persisting
for
more
than
12
weeks
after
the
onset
of
SARS-CoV-2
infection
that
cannot
be
explained
otherwise.
The
prevalence
self-reported
otorhinolaryngological
high.
aim
this
review
was
to
analyze
current
literature
regarding
actual
prevalence,
knowledge
etiopathology,
and
evidence-based
treatment
recommendations
otorhinolaryngology-related
symptoms.
A
systematic
search
articles
published
since
2019
in
PubMed
ScienceDirect
performed
resulted
108
articles.
These
were
basis
formed
comprehensive
series
consented
therapy
statements
on
most
important
Otorhinolaryngological
did
not
appear
isolated
but
part
multi-organ
syndrome.
Self-reported
often
confirmed
by
objective
testing.
estimated
anosmia,
dysgeusia,
cough,
facial
palsy,
hoarseness/dysphonia,
acute
hearing
loss,
tinnitus,
vertigo/dizziness
about
4%,
2%,
4-19%,
0%,
17-20%,
8%,
20%,
5-26%,
respectively.
There
are
manifold
theoretical
concepts
etiopathology
different
symptoms,
there
no
clear
proof.
This
certainly
contributes
fact
effective
specific
option
any
mentioned.
Healthcare
pathways
must
established
so
can
recognized
evaluated
otorhinolaryngologists
provide
counseling.
would
also
help
establish
selectively
include
patients
clinical
trials
investigating
therapeutic
concepts.
Language: Английский
Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders
Published: April 14, 2023
Since
the
worldwide
spread
of
infection
with
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
treating
taste
and
saliva
secretory
disorders
associated
disease
2019
(COVID-19)
has
become
one
most
critical
issues
in
COVID-19
era.
The
aim
present
study
was
to
update
information
on
treatments
being
applicable
such
oral
symptoms
discuss
their
pathogenic
mechanisms.
Promising
include
different
types
methods
using
tetracycline,
corticosteroid,
zinc,
stellate
ganglion
block,
phytochemical
curcumin,
traditional
herbal
medicine,
nutraceutical
vitamin
D,
photobiomodulation,
antiviral
drug,
malic
acid
sialagogue,
chewing
gum,
acupuncture,
and/or
moxibustion.
At
present,
however,
fully
validated
are
still
lacking
for
COVID-19-associated
ageusia/dysgeusia/hypogeusia
xerostomia/dry
mouth/hyposalivation.
An
appropriately
selected
treatment
healthcare
should
be
provided
patients
survivors
suffering
from
disorders.
Understanding
currently
available
options
is
required
dental
profes-sionals
because
they
not
only
experience
who
were
infected
SARS-CoV-2
or
recov-ered
but
first
aware
abnormal
salivary
secretion.
By
doing
so,
dentists
hygienists
can
play
a
crucial
role
managing
contribute
improving
health-related
quality
life
relevant
patients.
Language: Английский